Evaluation model of the Mexican national program for early cervical cancer detection and proposals for a new approach

Cancer Causes and Control

Volumn 9, Issue 3, 1998, Pages 241-251

  Lazcano Ponce, Eduardo C ^a   Buiatti, Eva ^b   Nájera Aguilar, Patricia ^a   Alonso De Ruiz, Patricia ^c   Hernández Avila, Mauricio ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b Ctro di Docum per la Salute   (Italy)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cervical cancer; Mexico; Pap test; Screening; Women

Indexed keywords

ARTICLE; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; FEMALE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; MEXICO; MODEL; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; SAMPLING; SCREENING; SOCIAL STATUS; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; FEMALE; HEALTH SERVICES; HUMANS; MASS SCREENING; MEXICO; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0031850661     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008875818033     Document Type: Article

References (39)

1. World Health Organization. The World Health Report 1995. Bridging the Gaps. Geneva, Switzerland: WHO, 1995.
2. Läära E, Day E, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organized screening programs. Lancet 1987; 1: 1247-9.
3. Restrepo HE, Gonzalez JL, Roberts E, Litvak J. Epidemiología y control del cáncer del cuello uterino en America Latina y el Caribe. Bol Sanit Panam 1987; 102: 578.
4. Estadísticas sobre tumores malignos en México. Dirección General de Estadística Informática y Evaluación. Salud Pública Mex 1997; 39: 388-99.
5. Programa Nacional de Prevención y Control del Cáncer Cervicouterino. Plan de Acción de 1996. Secretaría de Salud, México, 1996: 1-31.
6. Lazcano-Ponce E, Rascon R, Lozano R, Velasco E. Mortality from carcinoma of the uterine cervix in Mexico: Impact of screening 1980-1990. Acta Cytol 1996; 40: 506-12.
7. Norma Oficial Mexicana NOM-014-SSA2-1994, Para la prevención, tratamiento y control de cáncer del cuello del útero y de la mama en la atención primaria. México 1994.
8. Lazcano-Ponce E, Alonso P, López L, Hernández M. Quality control study on negative gynecological cytology in Mexico. Diagn Cytopathol 1994; 10: 10-14.
9. Herbert A. Achievable standards, benchmarks for reporting, criteria for evaluating cervical cytopathology. Cytopathology 1995; 6: 1-32.
10. Lazcano-Ponce E, Alonso P, López L, et al. Validity and reproducibility of cytologic diagnosis in a sample cervical cancer screening centers in Mexico. Acta Cytol 1997; 41: 277-84.
11. Hernández-Avila M, Lazcano-Ponce E, López L, Alonso P, Rojas R. Evaluación del programa de detección oportuna de cáncer cervical en México. Un estudio de casos y controles con base poblacional. Gaceta Médica de México 1994; 130: 201-9.
12. Walter SD. The estimation and interpretation of attributable risk in health research. Biometrics 1976; 32: 829-49.
13. Lazcano-Ponce E, Nájera-Aguilar P, Buiatti E, et al. The cervical cancer screening program in Mexico: problems with access and coverage. Cancer Causes Control 1997; 8: 698-704.
14. Devesa S. Cancer mortality, incidence and patient survival among American women. Women Health 1986; 11: 7-22.
15. Beral V, Hermon C, Muñoz N, Devesa S. Cervical cancer. Trends in Cancer Incidence and Mortality. Cancer Surveys. Imperial Cancer Research Fund 1994; 1920: 265-85.
16. Muñoz N, Crawford L, Coursaget P. HPV vaccines for cervical neoplasia. Lancet 1995; 345: 249.
17. Sehgal A, Singh V, Bhambhani S, Luthra U. Screening for cervical cancer by direct inspection. Lancet 1991; 338: 282.
18. Singh V, Sehgal A, Luthra K. Screening for cervical cancer by direct inspection. Br Med J 1992; 304: 534-5.
19. Murthy NS, Agarwal S, Prabhakar A, Sharma S, Das D. Estimation of reduction of life-time risk of cervical cancer through one life-time screening. Neoplasma 1993; 40: 255-8.
20. Van-Ootmarssen G, Habbema J, Van-Ballegoijen M. Predicting mortality from cervical cancer after negative smear test results. Br Med J 1992; 305: 449-51.
21. Parkin DM, Moss S. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. J Epidemiol Commun Health 1986; 409: 143-53.
22. Segnan N. Cervical cancer screening. Human benefits and human costs in the evaluation of screening programmes. Eur J Cancer 1994; 30A: 873-5.
23. Van-Ballegoijen M, Habbema J, Van-ootmarssen J, Koopmanschap A, Lubbe, Van-Agt H. Preventive Pap smears: striking the balance between costs, risks, and benefits. Br J Cancer 1992; 65: 930-3.
24. Lamont W, Symonds P, Brodic M, Nwabineli J, Gillis R. Age, socio-economic status and survival from cancer of cervix in the West of Scotland 1980-87. Br J Cancer 1993; 67: 351-7.
25. Juneja A, Murthy N, Sharma S, Shukla D, Roy M, Das K. Selective cervical cytology screening: discriminant analysis approach. Neoplasma 1993; 40: 401-4.
26. Dignan M, Sharp P, Blinson K, et al. Development of a cervical cancer education program for native American women in North Carolina. J Cancer Educ 1994; 9: 235-42.
27. Austoker J. Cancer prevention in primary care. Screening for cervical cancer. Brit Med J 1994; 309: 241-248.
28. Swaddiwudhipong W, Chaovakiratipong C, Nguntra P, Mahasakpan P, Lerdlukanavonge P, Koonchote S. Effect of a mobile unit on changes in knowledge and use of cervical cancer screening among rural Thai women. Int J Epidemiol 1995; 24: 493-8.
29. Coleman D, Day N, Douglas G, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer program. Eur J Cancer 1993; 29A(Suppl 4): S1-S38.
30. Koss L. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989; 261: 737-44.
31. Buntinx F, Brouwers M. Relation between sampling device and detection of abnormality in cervical smears: a meta analysis of randomised and quasi randomised studies. Br Med J 1996; 313: 1285-90.
32. Lazcano-Ponce E, Alonso de Ruiz P, Martinez C, Murgia L. Reproducibility study of cervical cytopathology in Mexico: A need for regulation and professional accreditation. Diagn Cytopatbol 1997; 17: 20-4.
33. Alonso P, Lazcano E, Quied G, Keebler C, Rosenthal D, Schenck U, Somrak T, Vooijs P, eds. Compendium on Quality Assurance, Proficiency Testing and Workload Limitations in Clinical Cytology. Chicago, Illinois (USA): Tutorials of Cytology, 1995: 115-21.
34. Miller B. Cervical Cancer Screening Programmes: Managerial Guidelines. Geneva, Switzerland: World Health Organization. 1992: 15-9.
35. Bishop A, Sherris J, Davis-Tsu V, Kilbourne-Brook M. Cervical dysplasia treatment: key issues for developing countries. Bull PAHO 1996; 30: 378-86.
36. Robles S. Introduction to the special issue: timely detection of cervical cancer. Bull PAHO 1996; 30: 285-9.
37. Muñoz N, Bosch X. Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention. Salud Publica Mex 1997; 39: 274-82.
38. Wheeler C. Preventive vaccines for cervical cancer. Salud Publica Mex 1997; 39: 283-7.
39. Herrero R, Schiffman M, Bratti C, et al. Evaluation of multiple screening techniques in a high risk area: the Guanacaste Project. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford, UK: Blackwell Science, 1997: 389-99.